bibliographic resource 2494573 [br/2494573]
https://w3id.org/oc/corpus/br/2494573
- is a
-
- title
-
- A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation â An NRG Oncology/Gynecologic Oncology Group study
- publication date
-
- contributor
-
- format
-
- identifier
-
- part of
-